Dr Keith Tsui

Medopad

Keith is the lead for life science partnerships in the clinical product team. In addition, Keith is also responsible for developing the strategy to demonstrate outcome and evidence for remote patient monitoring within Medopad. Prior to Medopad, Keith was a management consultant at Carnall Farrar, a healthcare consulting firm. Keith completed his medical training at The University of Hong Kong and holds a MPhil in Bioscience Enterprise from University of Cambridge.

dont miss

Remote Patient Monitoring: Bringing the Hospital into the Home

Patients with rare and chronic disease spend 95% of their time outside hospital, where clinicians typically have no or intermittent access to patient health data.
Here, we explore how a remote patient monitoring solution can be applied within the care pathway for oncology, to improve visibility of patient progress, impact patient engagement, and improve pathway efficiencies. Oncology monitoring at King’s College Hospital, HCA, and Sussex Cancer Centre will be explored.

Dr Keith Tsui will be speaking in the following theatre:

Theatre 10 - Wednesday 11.45 - 12.15: Remote Patient Monitoring: Bringing the Hospital into the Home

EVEN MORE SEMINARS

  • Luca Boldrini: Speaking at the Oncology Convention

    Luca Boldrini
    Università Cattolica del Sacro Cuore, Roma, Italia

    Radiomics applications rectal cancer: the MRIdian perspective

  • Dr. Omar Milhem: Speaking at the Oncology Convention

    Dr. Omar Milhem
    Pharma Medico Ltd

    Clinical Management of Proteoglycan Follicular Atrophy in Female Hair Loss

  • Professor Hisham Mehanna: Speaking at the Oncology Convention

    Professor Hisham Mehanna
    InHANSE, Institute of Cancer and Genomic Sciences, University of Birmingham

    Clinical trials that change patient care and the lessons learnt

  • Jocelyn Harding CEB DipDH: Speaking at the Oncology Convention

    Jocelyn Harding CEB DipDH
    Oralieve UK

    The importance of mouth care for cancer patients

  • Stefan Schuster: Speaking at the Oncology Convention

    Stefan Schuster
    Datar Cancer Genetics Limited

    Clinical Utility of Liquid Biopsy in Brain Tumors